GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or symptoms in adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback